Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarizax for Persistent Asthma Control After Tezepelumab
NCT07013123Phase 3Not yet recruiting
- Sponsor
- CHU Montpellier
- Start
- Jul 2025
- Primary completion
- Aug 2029
- Modality
- Allergy Immunotherapy
01
Overview
A Phase 3 trial of House dust mite allergen extract in asthma, house dust mite allergy, sponsored by CHU Montpellier. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
House dust mite allergen extract
03
Conditions
asthmahouse dust mite allergy
Beyond the preview
Go deeper on NCT07013123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013123.